Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Actinium Pharmaceuticals
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00672165
First received: May 2, 2008
Last updated: May 13, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: July 2015
  Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)